It is imperative that by targeting the EphA3, EphA2, and EphB2 receptors at once, we will be targeting not just the tumor cells, but also key components within the GBM microenvironment that allow GBM to sustain and grow. This evidence concerns the gene EPHA2 and glioblastoma.